Bio-Optronics Builds Oncology-Specific Features into CTMS
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor. These features include adaptive and dynamic protocol design; billing compliance function that allows organizations managing and executing oncology studies to create multiple versions of cost-allocation grids for multi-arm trials, providing more accurate billing information with less time and effort; and financial tools to accommodate complex and changing protocols, allowing organizations to effectively bill for recurring visits and other complexities that result from oncology protocol design. In addition to this, organizations can set specific Medicare coverage designations at specific sites.Finally, the CTMS contains National Cancer Institute reporting functionality that creates NCI-compliant reports and allows researchers to adhere to NCI grant requirements more easily.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
